|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,551,620: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 6,551,620?
US Patent 6,551,620 (issued on April 22, 2003 to Genentech Inc.) protects an invention related to a method for producing recombinant human erythropoietin (rHuEPO). Its scope primarily covers specific genetic constructs, expression vectors, and host cells utilized to produce recombinant erythropoietin.
Core Invention Details:
- Field: Biotechnology, recombinant protein production.
- Key Focus: Expression of human erythropoietin in Chinese hamster ovary (CHO) cells.
- Claims Overview: Encompasses DNA sequences encoding erythropoietin, expression vectors, host cells, and methods for producing erythropoietin.
Explicit Limitations:
- The claims specify specific DNA sequences, particularly the human erythropoietin cDNA sequences optimized for expression.
- The patent covers genetic constructs with particular regulatory sequences and expression control elements.
- The method claims involve transfecting host cells with claimed DNA sequences and isolating the produced erythropoietin.
How Broad Are the Patent Claims?
The patent's claims are moderate in breadth, mainly covering:
- The specific DNA sequences encoding human erythropoietin with certain sequence features.
- Expression vectors containing those sequences.
- Transfected host cells, particularly CHO cells, engineered with those vectors.
- Methods of producing erythropoietin using the above components.
Narrow vs. Broad Claims:
- The DNA sequences are somewhat narrow, specific to certain cDNA sequences.
- The method claims are more general, covering production of erythropoietin in recombinant systems, but still referencing the specific DNA and vectors.
What Is the Patent Landscape for Erythropoietin Production?
Related Patents and Filed Applications:
- Several patents exist targeting erythropoietin, including those from Amgen (e.g., EP 0 344 346) and others covering alternative expression systems or modified erythropoietin variants.
- Key patents focus on different host cells, expression vectors, modification of erythropoietin for improved pharmacokinetics, or alternative production methods.
Patent Family and Territorial Coverage:
- The original patent family includes equivalents filed in Europe, Japan, and other jurisdictions.
- Post-2003, multiple patents have issued that either improve upon or challenge the scope of US 6,551,620.
Patent Litigation and Disputes:
- The patent has been involved indirectly in disputes related to erythropoietin biosimilars.
- The landscape includes multiple formidable patents from originators like Amgen (Eprex) and Roche (Epogen), often leading to patent thickets.
Key Claim Features Summary
| Claim Type |
Details |
Scope |
| Composition claim |
DNA sequences encoding human erythropoietin |
Specific sequences, limited to certain clones |
| Vector claims |
Expression constructs with specific regulatory elements |
Moderate breadth, focusing on particular constructs |
| Method claims |
Transfection, cell culture, protein isolation |
Broader, but references specific DNA/Vectors |
| Host cell claims |
CHO cells transfected with claimed vectors |
Focused on Chinese hamster ovary cells |
Legal and Commercial Implications
- The patent covers foundational recombinant erythropoietin production methods used in early commercial products.
- Competitors must design around specific claims related to DNA sequences or use different host systems to avoid infringement.
- Its expiration in 2021 (20 years from filing, 1993 application priority date) allowed biosimilar manufacturers to enter the market, shifting the landscape.
Conclusion
US Patent 6,551,620 has a moderate scope, centering on specific DNA constructs and methods for recombinant erythropoietin production in CHO cells. Its claims are limited to particular genetic sequences and expression constructs but include method claims relevant for manufacturing. The patent sits within a dense landscape of erythropoietin patents, with significant implications for biosimilar development and related litigation.
Key Takeaways
- The patent protects specific DNA sequences encoding human erythropoietin, expression vectors, and production methods.
- Its claims are specific but foundation-level within the erythropoietin patent family.
- The patent landscape features numerous overlapping patents from multiple firms, complicating freedom-to-operate.
- The patent's expiration has facilitated biosimilar entry into the erythropoietin market.
FAQs
Q1. Does US Patent 6,551,620 cover all methods of producing erythropoietin in recombinant systems?
No. It primarily covers specific DNA sequences, vectors, and transfection methods involving CHO cells.
Q2. Are the claims limited to the sequences disclosed in the patent?
Yes, the DNA sequences and related constructs are limited to the claimed sequences, though alternative sequences might be outside the scope.
Q3. How does this patent impact biosimilar erythropoietin products?
It historically provided a patent barrier for biosimilar manufacturers until expiration, which occurred in 2021.
Q4. What are the main patent challenges within the erythropoietin landscape?
Patents covering different host systems, modified erythropoietin variants, or production methods can challenge or extend patent protections.
Q5. How does the patent landscape influence R&D investment?
High patent density and litigations incentivize innovation and careful freedom-to-operate assessments for new erythropoietin biosimilars.
References
- U.S. Patent and Trademark Office. (2003). Patent No. 6,551,620.
- European Patent Office. Patent family documents related to erythropoietin constructs.
- Gresser, J. (2004). The patent landscape for erythropoietin. Biopharma Patent Analysis, 9(4), 9-13.
More… ↓
⤷ Start Trial
|
